Inventor · disambiguated record
Rafet Basar
Also filed as: BASAR RAFET
1 granted patent·23 pending applications·0 citations·filing 2018–2025
14Inventor score
Files withUNIV TEXAS24
Top patents by PatentIndex Score
24 records- 0175US12310988B2BCMA chimeric antigen receptors and uses thereofUNIV TEXAS·Filed 2024·Granted May 27, 2025·0 cites·3 claims
- 0261US2025228942A1Methods for activation and expansion of engineered natural killer cells and combinations with antibodiesUNIV TEXAS·Filed 2023·Application pending·0 cites
- 0359US2025255905A1Bcma chimeric antigen receptors and uses thereofUNIV TEXAS·Filed 2025·Application pending·0 cites
- 0457US2025249098A1Cryopreservation of nk cell products for off-the-shelf immunotherapyUNIV TEXAS·Filed 2023·Application pending·0 cites
- 0555US2024382593A1Antibody loaded immune cells and methods for use in cancer treatmentUNIV TEXAS·Filed 2022·Application pending·0 cites
- 0654US2025074950A1Methods for production of therapeutic immune cells having enhanced metabolic fitness and compositions thereofUNIV TEXAS·Filed 2022·Application pending·0 cites
- 0754US2024408203A1Engineering nk cells with a car construct with optimal signalingUNIV TEXAS·Filed 2022·Application pending·0 cites
- 0854US2024252539A1Chimeric antigen receptor to target hla-g-positive cancersUNIV TEXAS·Filed 2022·Application pending·0 cites
- 0953US2024325444A1Chimeric antigen receptor to target trop-2-positive cancersUNIV TEXAS·Filed 2022·Application pending·0 cites
- 1053US2024269285A1Polypeptides targeting cd70-positive cancersUNIV TEXAS·Filed 2022·Application pending·0 cites
- 1153US2024189357A1Chimeric antigen receptors to target cd5-positive cancersUNIV TEXAS·Filed 2022·Application pending·0 cites
- 1252US2024165162A1Methods for activation and expansion of natural killer cells and combinations with bispecific antibodiesUNIV TEXAS·Filed 2022·Application pending·0 cites
- 1352US2025281612A1Cd27-extracellular domain car to target cd70-positive tumorsUNIV TEXAS·Filed 2022·Application pending·0 cites
- 1452US2024325443A1Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapyUNIV TEXAS·Filed 2022·Application pending·0 cites
- 1549US2022378739A1Natural killer cell immunotherapy for the treatment of glioblastoma and other cancersUNIV TEXAS·Filed 2020·Application pending·0 cites
- 1648US2023210902A1Sars-cov-2-specific t cellsUNIV TEXAS·Filed 2021·Application pending·0 cites
- 1748US2023383257A1Production of megakaryocytes and platelets in a co-culture systemUNIV TEXAS·Filed 2021·Application pending·0 cites
- 1846US2022389383A1Large-scale combined car transduction and crispr gene editing of nk cellsUNIV TEXAS·Filed 2020·Application pending·0 cites
- 1946US2022401479A1Large-scale combined car transduction and crispr gene editing of t cellsUNIV TEXAS·Filed 2020·Application pending·0 cites
- 2046US2022403418A1Large-scale combined car transduction and crispr gene editing of b cellsUNIV TEXAS·Filed 2020·Application pending·0 cites
- 2145US2022288121A1Cell cryopreservation mediumUNIV TEXAS·Filed 2020·Application pending·0 cites
- 2244US2021230548A1Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockadeUNIV TEXAS·Filed 2019·Application pending·0 cites
- 2344US2023045174A1Large-scale combined car transduction and crispr gene editing of msc cellsUNIV TEXAS·Filed 2020·Application pending·0 cites
- 2440US2021147800A1Methods for producing regulatory immune cells and uses thereofUNIV TEXAS·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Rafet Basar files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →